Tag: NYSE:MAIA

MAIA’s novel telomere-targeting therapy being evaluated as a third-line treatment for advanced non-small cell lung cancer

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Name

This field is for validation purposes and should be left unchanged.

HomeTagsNYSE:MAIA